List of works by Scott Gettinger

A decade of advances in treatment for advanced non-small cell lung cancer

scientific article published on December 2011

A phase Ib/II study of cabozantinib (XL184) with or without erlotinib in patients with non-small cell lung cancer

scientific article

Acquired resistance of EGFR-mutant lung adenocarcinomas to afatinib plus cetuximab is associated with activation of mTORC1.

scientific article

Activity of IPI-504, a Novel Heat-Shock Protein 90 Inhibitor, in Patients With Molecularly Defined Non–Small-Cell Lung Cancer ⬇️

scientific article published on October 12, 2010

An Advanced Practice Nurse Coordinated Multidisciplinary Intervention for Patients with Late-Stage Cancer: A Cluster Randomized Trial

scientific article

Association of Acute Interstitial Nephritis With Programmed Cell Death 1 Inhibitor Therapy in Lung Cancer Patients

scientific article

Axitinib: The evidence of its potential in the treatment of advanced thyroid cancer ⬇️

scientific article published on June 15, 2010

B7-H1/PD-1 blockade therapy in non-small cell lung cancer: current status and future direction

scientific article published on July 2014

Circulating and tumor-based biomarkers predict clinical activity in cancer patients treated with the engineered anti-PD-L1 antibody MPDL3280A

Clinical and Histologic Features of Lichenoid Mucocutaneous Eruptions Due to Anti-Programmed Cell Death 1 and Anti-Programmed Cell Death Ligand 1 Immunotherapy.

scientific article published on 13 July 2016

Complications of therapy in cancer patients: Case 2. Scrotal ulceration during all-trans-retinoic acid therapy for acute promyelocytic leukemia

scientific article published in November 2004

Continued use of afatinib with the addition of cetuximab after progression on afatinib in patients with EGFR mutation-positive non-small-cell lung cancer and acquired resistance to gefitinib or erlotinib

scientific article published on 31 August 2017

Current status of vandetanib (ZD6474) in the treatment of non-small cell lung cancer ⬇️

scientific article published on September 13, 2010

Distinct immunologic changes in vivo following combination versus individual PD-1 or CTLA-4 checkpoint blockade in human cancer

Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutations

scientific article

Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNA.

scientific article published on 12 January 2018

Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: Results From the CA209-003 Study.

scientific article published on 23 March 2018

Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors

scientific article

High SOX2 levels predict better outcome in non-small cell lung carcinomas

scientific article

High expression of BCL-2 predicts favorable outcome in non-small cell lung cancer patients with non squamous histology

scientific article

High expression of mammalian target of rapamycin is associated with better outcome for patients with early stage lung adenocarcinoma

scientific article

Immune checkpoint modulation for non-small cell lung cancer

scientific article published on 01 May 2015

Immune therapies for lung cancer

scientific article

Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer

scientific article published on 12 October 2017

Intratumoral characteristics of tumor and immune cells at baseline and on-treatment correlated with clinical responses to MPDL3280A, an engineered antibody against PD-L1.

scientific article published on 7 November 2013

Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer

scientific article published on 27 June 2016

Nivolumab Plus Erlotinib in Patients with Epidermal Growth Factor Receptor-Mutant Advanced Non-Squamous Non-Small Cell Lung Cancer.

scientific article

Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer

scientific article published on 27 June 2016

P2.36: Nivolumab (nivo) in Patients (pts) With Advanced (adv) NSCLC and Central Nervous System (CNS) Metastases (mets): Track: Immunotherapy

scientific article

PD-1 Axis Inhibitors in EGFR- and ALK-Driven Lung Cancer: Lost Cause?

scientific article published on 28 July 2016

Perfect ALKemy: optimizing the use of ALK-directed therapies in lung cancer

scientific article

Phase 1 study of aflibercept administered subcutaneously to patients with advanced solid tumors

scientific article

Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH).

scientific article

Possible Interaction of Anti-PD-1 Therapy with the Effects of Radiosurgery on Brain Metastases

scientific article published on 18 March 2016

Precipitation of autoimmune diabetes with anti-PD-1 immunotherapy

scientific article published in April 2015

Reduced NF1 expression confers resistance to EGFR inhibition in lung cancer

scientific article

Targeted therapy in advanced non-small-cell lung cancer

scientific article published on June 2008

Treatment of lung cancer in older patients

scientific article published on December 2007

Treatment of stage IV non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines

scientific article

Paulina is supported by:

About Paulina

Help